Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.01 – $0.22
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.3M | $7.0M | $1.5M | $7.8M | $1.7M | $2.3M | $1.9M |
| Cost of revenue | $280.0K | $280.0K | $280.7K | $280.0K | $280.0K | $280.0K | $280.7K | $186.1K |
| Gross profit | $1.1M | $1.0M | $6.7M | $1.3M | $7.5M | $1.4M | $2.0M | $1.9M |
| Gross margin | 79.6% | 78.6% | 96.0% | 81.9% | 96.4% | 83.1% | 87.9% | 100.0% |
| R&D | $3.2M | $5.7M | $5.9M | $4.1M | $9.1M | $12.7M | $9.0M | $7.7M |
| Operating income | −$6.1M | −$10.1M | −$10.5M | −$5.8M | −$4.3M | −$13.0M | −$8.8M | −$8.1M |
| EBITDA | −$5.9M | −$9.8M | −$10.2M | −$8.8M | −$13.6M | −$16.3M | −$10.0M | −$9.3M |
| Net income | −$4.6M | −$8.5M | −$3.6M | −$7.7M | −$5.4M | −$14.3M | −$9.7M | −$9.4M |
| Net margin | -332.0% | -647.4% | -51.9% | -497.4% | -70.1% | -863.0% | -420.8% | -498.1% |
| EPS (diluted) | -0.05 | -0.08 | -0.03 | -0.06 | -0.04 | -0.10 | -0.05 | -0.05 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.02 | $-0.02–$-0.02 | 1 |
| 2027 | $32M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2028 | $2M | $-0.09 | $-0.09–$-0.09 | 1 |
Forward consensus · source: Financial Modeling Prep
CYNATA THERAPEUTICS LTD
No one on the platform currently holds CYYNF.
No tracked institution reports a position in CYYNF as of their last filing.
No one on the platform has traded CYYNF yet.
| +0.00% |
| $42M |
| — |
| MMIRFMedMira Inc. | $0.05 | +0.00% | $34M | — |
| NVYTFNovacyt S.A. | $0.48 | -0.00% | $35M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.